Finanzen von Intellia Therapeutics Inc (NTLA)NTLAIntellia Therapeutics Inc

Evaluating the bottom line, INTELLIA THERAPEUTICS, INC. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1472.25%, while the net margin is -1392.27%. These profitability ratios, combined with a Return on Equity (ROE) of -55.44%, provide a clear picture of how effectively NTLA converts its operational activities into shareholder value.

In the context of the broader market, NTLA competes directly with industry leaders such as RXRX and SEPN. With a market capitalization of $1.84B, it holds a significant position in the sector. When comparing efficiency, NTLA's gross margin of 100.00% stands against RXRX's -49.82% and SEPN's 100.00%. Such benchmarking helps identify whether INTELLIA THERAPEUTICS, INC. is trading at a premium or discount relative to its financial performance.

Intellia has shown significant revenue growth, with Q2 2026 revenue at 7659000 USD, but continues to report substantial net losses, with Q2 2026 net income at -106634000 USD. The gross margin remains strong at 100%, indicating effective cost management in revenue generation.